Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

Shastri Stresses the Need for Risk Stratification to Personalize Decisions in MDS

March 29th 2021

Aditi Shastri, MBBS, discusses risk stratification tools, her treatment algorithm for patients with low-risk MDS, and the role of luspatercept in this population.

Single Priming Dose of Tremelimumab Plus Durvalumab Shows Encouraging Clinical Activity, Safety in Advanced HCC

March 28th 2021

A regimen comprised of a single 300-mg priming dose of tremelimumab and 1500 mg of durvalumab every 4 weeks yielded favorable efficacy and an acceptable safety profile in patients with advanced HCC.

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

March 25th 2021

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

Farletuzumab/Chemo Fails to Improve PFS in Platinum-Sensitive, Recurrent Ovarian Cancer With Low CA-125

March 25th 2021

The addition of farletuzumab to carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin did not demonstrate superiority over placebo plus chemotherapy in patients with platinum-sensitive recurrent ovarian cancer who are in their first relapse and have low cancer antigen-125 levels.

ctDNA Possesses the Potential to Revolutionize Care in CRC and Beyond

March 23rd 2021

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Novel Therapeutics Target Epigenetic Regulation, Immune System to Boost Activity in AML

March 20th 2021

Kira Gritsman, MD, PhD, discusses several novel agents that are under investigation to improve outcomes in poor-prognosis subsets of patients with AML, early data supporting these approaches, and the potential impact of these options on the treatment paradigm.

Cancer Screening, Diagnosis Rates Nearly Recover to Pre–COVID-19 Levels in the Northeastern United States

March 17th 2021

Although cancer screening rates and ensuing diagnoses dropped significantly during the height of the COVID-19 pandemic, testing rates from June 2020 through September 2020 have nearly returned to pre-pandemic levels.

Ruxolitinib Induces Prolonged Efficacy in Steroid-Refractory Acute GVHD

March 16th 2021

Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.

Camidanlumab Tesirine Under Investigation in Relapsed/Refractory Hodgkin Lymphoma

March 16th 2021

The safety and efficacy of the antibody-drug conjugate camidanlumab tesirine is under investigation in patients with relapsed/refractory Hodgkin lymphoma as part of a phase 2 clinical trial, which recently completed accrual.

Novel Targeted and Immunotherapeutic Agents Reshape Metastatic Urothelial Cancer Landscape

March 12th 2021

Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.

Agents Targeting MET, RET, and Previously “Undruggable” KRAS Advance Treatment in NSCLC

March 11th 2021

Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.

Venetoclax/HMA Approach Revolutionizes Care for Certain Subsets of AML

March 10th 2021

Kira Gritsman, MD, PhD, discusses the significance of the VIALE-A trial examining venetoclax plus azacitidine in older patients with AML and the emergence of minimal residual disease as an important end point in clinical trials.

Ciombor Cites Challenges in Optimizing Care for Locally Advanced Rectal Cancer

March 10th 2021

Determining the appropriate sequencing for chemotherapy and radiation in patients with locally advanced rectal cancer is important and may depend on whether the goal of therapy is nonoperative management.

D’Angelo Details Combos Designed to Produce Durable Activity in Relapsed/Refractory DLBCL

March 9th 2021

Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies and the challenges with using a 5-drug regimen.

Belumosudil: Poised to Become Necessity in Chronic GVHD

March 9th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the potential clinical implications should belumosudil gain FDA approval in chronic GVHD.

Local Management in Stage IV Breast Cancer Requires More Refinement

March 5th 2021

Although there is evidence to suggest that surgery with or without radiation therapy can be utilized in some patients with stage IV breast cancer who have experienced locoregional progression or symptoms to some success with regard to locoregional disease control, most patients will not achieve a survival benefit.

Frontline Nivolumab Plus Chemo Shows Practice-Changing Potential in GI Cancers

March 5th 2021

Yelena Y. Janjigian, MD, discussed the promise of nivolumab plus chemotherapy in patients with PD-L1–positive advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma, as well as important biomarkers that should be used to guide sequencing decisions.

Approaches Abound for Managing Symptoms Associated With Myelofibrosis

March 4th 2021

Srdan Verstovsek, MD, PhD, shares recommendation updates for myelofibrosis treatment and emerging options under exploration to effectively manage disease-related symptoms.

Novel Concepts to Improve Survival, Manage Associated Symptoms in Myelofibrosis

March 2nd 2021

Several novel therapeutics such as JAK inhibitors and luspatercept have been developed for the treatment of patients with myelofibrosis and its associated symptoms, paving the way for improved survival rates and new combination strategies over the last decade.

New Methods for MRD Testing Help to Predict Relapse Across Multiple Leukemia Subtypes

March 2nd 2021

Minimal residual disease has helped to predict relapse in numerous leukemia subtypes, with novel testing methods helping to identify the biomarker at a higher sensitivity than ever before.